Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator

Menlo Park, Calif., December 5, 2024 – Nuvig Therapeutics, Inc., (“Nuvig”) a privately held biotechnology company developing novel immunomodulatory therapeutics for patients with inflammatory autoimmune diseases, announced today the closing of a $161 million Series B financing. The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture… The post Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator appeared first on Nuvig